Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, proudly announces the appointment of David Bakey as GM of the Consumer Division. In this role, Bakey will lead the global expansion of Eko’s hardware and software solutions across retail and direct-to-clinician channels, building on its current base of over 500,000 healthcare professionals and extending its reach to millions globally in the coming years.
Bakey joins Eko with an impressive background, marked by success in both B2C and B2B growth across diverse industries including Consumer Packaged Goods (CPG), PropTech, EdTech, and FinTech. He previously served as Chief Operating Officer at Belong and as Vice President of Consumer at Harry’s, where he played a pivotal role in scaling direct-to consumer operations. His experience also includes leading growth teams at Lynda.com (acquired by LinkedIn) and DailyPay, where he excelled at driving revenue, enhancing profitability, and building high-performance teams.
"David’s visionary leadership is perfectly aligned with Eko’s mission to expand access to our groundbreaking technology to millions of healthcare professionals around the world," said Connor Landgraf, CEO and co founder of Eko. "His deep expertise in consumer engagement and strategic growth will be instrumental as we expand clinician offerings, making advanced early detection solutions more accessible and user-friendly."
Bakey’s appointment follows Eko’s successful $41 million Series D funding round, which aimed to expand access to its AI-driven disease detection technologies in the U.S. and globally. This latest investment will support Eko’s strategic initiatives to scale operations and drive innovations in heart and lung disease detection.
"Eko is revolutionizing point-of-care medicine by empowering clinicians with modern, AI powered stethoscope replacements that leverage machine learning to detect early signs of heart and lung disease, profoundly improving patient care," said David Bakey. "I am excited about the opportunity to apply my background in consumer growth to ensure this potentially lifesaving technology reaches the hands of millions of healthcare professionals in the coming years. The opportunity for impact here is unmatched."
Eko’s recent milestones include achieving FDA clearance for its Low Ejection Fraction (Low EF) AI, as well as surpassing 500,000 healthcare professionals using its products. These accomplishments reflect Eko’s steadfast dedication to improving early detection and treatment outcomes for heart and lung diseases.
MKT-0003491